AzTrials
AzTrials

CataractNCT03152500

Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study

A study testing FEMTIS 313G IOL and Acrysof SN60WF IOL in people with Cataract, run by Maastricht University Medical Center at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Read more about this study

Who is it for?
Ages 40 years and olderHealthy volunteers can take part
Conditions the study is for
Cataract
What is being tested?
FEMTIS 313G IOL and Acrysof SN60WF IOL
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteNetherlands
Study dates
1 Jan 2017to 30 Oct 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Minimum 40 years of age
  • Cataracta Senilis
  • Expected postoperative astigmatism ≤ 0.75 D (combination with FLACS AK is tolerated up to 1.25 D preoperative astigmatism)
  • IOL power calculation between +10.00 D and 27.00 D
  • Expected postoperative best-corrected visual acuity of logMAR +0.3 or better
  • If eligible, availability to undergo second eye surgery within 2 weeks of the first eye surgery
  • Willing and able to comply with scheduled visits and other study procedures
  • Signed informed consent.

Who cannot join

  • Traumatic cataract
  • Previous corneal surgery and/or reshaping
  • Clinically significant corneal endothelial dystrophy (e.g., Fuchs' dystrophy)
  • Irregular astigmatism
  • History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)
  • Extensive age related macular degeneration (atrophic or exudative age-related macular degeneration or numerous soft drusen)
Show all 15Show fewer
  • Extensive visual field loss (e.g., glaucoma, history of cerebral vascular accidents, etc.)
  • Extensive diabetic macular disease
  • Amblyopia, strabismus
  • Keratoconus
  • Pseudoexfoliation syndrome or other capsule or zonular abnormalities that could affect postoperative centration or tilt of the IOL
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)
  • Cognitive, cerebral or concentration disorders (e.g. dementia, Parkinson, etc.)
  • Suturing of incision required at time of surgery
  • Complications during surgery of the first eye.

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Maastricht University Medical Centre

    Maastricht, Limburg, 6202 AZ

Other trials in Netherlands

About this study

Official title: A Randomised, Subject-masked Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study

In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Therefore, the investigators will perform this randomized control trial.

Read the detailed description

Cataract is a clouding of the crystalline lens which causes vision loss and blindness if untreated. Cataract surgery is the most frequently performed surgical intervention in medicine with an incidence of 880 surgeries per 100.000 population in 2010 amounting to a total number of over 160.000 surgeries per year in the Netherlands.1,3 The number of individuals with cataracts is predicted to reach 30 million by the year 2020.2 Due to aging of the general population this number of cataracts will only grow in the future.

For the last decade conventional phacoemulsification cataract surgery (CPCS) is the dominant form of cataract surgery in developed countries, accounting for over 90 percent of these procedures.4 The basic phacoemulsification procedure has remained largely unchanged over the past 20 years, including a series of steps: creating corneal incision, capsulorhexis and lensfragmentation.4 Although highly successful, each of the steps mentioned above are created manually which affects the safety and effectiveness of the procedure.

Since the first human eye was treated by femtosecond laser cataract surgery in 2008, the femtosecond-laser assisted cataract surgery (FLACS) became an innovative growing new technology in the world of cataract surgery.4-7 Femtosecond-lasers are capable of performing some of the most delicate and essential key steps during cataract surgery: capsulotomy, lens fragmentation, and corneal incisions. 'Automating' these steps and performing them with increased precision could lead to an improved quality of capsulotomy, easier lens fragmentation, and more precisely positioned corneal incisions, which in turn, lead to improved visual and refractive outcomes, a decrease in intra- and postoperative complication rates, and increased quality of life.

In order to remove the crystallized human lens, a circular opening in the capsular lens bag, capsulotomy, needs to be created. After removing the lens an intraocular lens (IOL) can be inserted in the empty capsule bag. However, one of the factors affecting postoperative achieved visual acuity and refraction, is the behaviour of this IOL in the capsular bag. Preoperative measurements need to be obtained in order to calculate the required IOL. One of the challenges of these IOL calculations is determining exactly where in the eye the IOL will end up, the effective lens position (ELP). The position of the IOL is crucial for the IOL's general performance because it influences the postoperative IOL tilt, decentration, and posterior capsule opacification (PCO). Considering the anatomical variety between patients, the predictability of an individual's ELP remains an educated guess.

The ELP, and therefore the amount of IOL tilt, decentration and PCO, of an IOL is mainly influenced by the interaction between the IOL and the lens capsule, especially during the time of capsule shrinkage. Theoretically, the positive optical effect of an IOL is lost when there is more than 7 degrees of tilt or more than 0.4 mm of decentration.8 Furthermore, studies have shown the effect of axial displacement of an IOL on refractive error. There is approximately 1.25 D change per millimetre of the IOL's longitudinal displacement.9 This reflects the importance of a stable and predictable ELP.

As mentioned above, the anatomy of an individual's eye is unique and therefore, each ELP will be different when placing the IOL in the capsular bag. Therefore, a new lens type has been developed: the FEMTIS® FB-313 laser lens (FEMTIS-IOL, Oculentis). This IOL has a special haptic system and is designed to be clasped in the capsular bag opening and therefore, the ELP of this IOL is theoretically more stable and predictable, resulting in a higher predictability of refractive and visual outcomes. However, in order to provide as much stability as possible a (nearly) perfect capsulotomy is needed. Several comparative studies have shown that femtosecond-lasers produce a more precise, circular, reproducible, and better centered capsulotomy compared to conventional manual capsulorhexis.6-7 The combination between the femtosecond-assisted capsulotomy and the implantation of a FEMTIS-IOL in the capsular opening, could definitely contribute to the search of perfection in cataract surgery.

In this study the investigators will investigate the stability of lens position and the visual outcome after implantation of the new FEMTIS-IOL using FLACS capsulotomy compared to conventional placement of the IOL in the capsular bag. So far, there are no published studies using the FEMTIS-IOL. Therefore, the investigators will perform this randomized control trial.

Conditions
Cataract
Being tested
FEMTIS 313G IOL, Acrysof SN60WF IOL
Keywords
IOL, Stability, FEMTIS IOL, Acrysof IOL, FLACS, Capsulotomy
Medical subject headings
Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FEMTIS 313G IOLDevice

    Haptic design that enclaves the capsulorrhexis

  • Acrysof SN60WF IOLDevice

    IOL in the bag

Study groups in NCT03152500
Study groupRoleWhat they receive
FEMTIS IOLExperimentalThe FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
Receives: Device: FEMTIS 313G IOL
Acrysof IOLActive comparatorThe Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
Receives: Device: Acrysof SN60WF IOL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Decentration:To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs

    To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs

    Measured: 13 weeks/3months

Secondary outcomes (3)
  1. Rotation stability

    To compare rotation stability between both IOls using retro-illumination slitlamp photographs

    Measured: 13 weeks/3months

  2. Tilt: To compare the amount of tilt between both IOls using Scheimpflug images

    To compare the amount of tilt between both IOls using Scheimpflug images

    Measured: 13 weeks/3months

  3. Visual outcomes

    Uncorrected (UDVA) and corrected (CDVA) distance visual acuity using ETDRS reading charts.

    Measured: 13 weeks/3months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2017
  2. Study start1 Jan 2017
  3. Primary completion30 Sep 2017
  4. Study completion30 Oct 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03152500
Sponsor's protocol ID
NL58195.068.16
Status last verified
May 2017
First submitted
8 May 2017
Last updated
2 May 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No IPD will be shared

Questions about this trial

What is this clinical trial studying?

A study testing FEMTIS 313G IOL and Acrysof SN60WF IOL in people with Cataract, run by Maastricht University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Decentration:To compare the amount of decentration between FEMTIS IOL versus a standard monofocal IOL (Acrysof monofocal IOL) using retro-illumination slitlamp photographs (time frame: 13 weeks/3months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in